News
SWOBY
21.77
NaN%
--
Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK 6.96, revenue of SEK 9.12B; updates FY2026 outlook
Seeking Alpha · 1d ago
Lilly, Pfizer, J&J among winners of EU drug recommendations this month
Seeking Alpha · 10/16 12:33
Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK 4.00, revenue of SEK 7.84B
Seeking Alpha · 07/16 11:52
Jazz, AstraZeneca, Astellas: Foreign Healthcare's strongest Quant picks
Seeking Alpha · 05/07 11:50
Weekly Buzz: MGNX Resumes LINNET; GSK Wins China Nod; FDA Okays Waters; NBIX Snaps Up SLNO
NASDAQ · 04/10 14:00
Health Canada Approves Swedish Orphan Biovitrum's EMPAVELI In C3G And Primary IC-MPGN Kidney Disease
NASDAQ · 04/10 07:13
The top-performing pharma and biotech stocks as group sees resurgence
Seeking Alpha · 02/13 19:01
Swedish Orphan Biovitrum AB reports Q4 results
Seeking Alpha · 02/05 11:39
Apellis upgraded at BofA on launch trajectory for kidney disease therapy
Seeking Alpha · 01/21 17:15
Sobi, Apellis win EU nod for Aspaveli against rare kidney diseases
Seeking Alpha · 01/16 12:39
SOBI: 2025 Revenue, Adj. EBITA Margin Higher Than Prior Guidance
NASDAQ · 01/15 12:33
Sobi Reports Positive Phase 2a EMBRACE Study Results For Gamifant In IFN?-Driven Sepsis
NASDAQ · 01/08 03:30
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO
NASDAQ · 12/20/2025 05:44
Sobi To Acquire Arthrosi Therapeutics
NASDAQ · 12/15/2025 06:38
Sobi Announces CHMP's Positive Opinion For Aspaveli
NASDAQ · 12/12/2025 13:30
More
Webull provides a variety of real-time SWOBY stock news. You can receive the latest news about Swedish Orphan Biovitrum AB through multiple platforms. This information may help you make smarter investment decisions.
About SWOBY
Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.